Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting
Share Article
Trial in progress poster: Phase 1 & Phase 2a, first-in-human study (FIH) of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors NEW YORK (PRWEB) June 03, 2021 Dracen Pharmaceuticals Inc., announced today that a poster presentation updating the ongoing Phase 1/2a, FIH study of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors will be presented during the trial in progress session at the ASCO virtual meeting June 4th- 8th, 2021.
The presentation details are as follows: Title: Phase 1 & Phase 2a, first-in-human study (FIH) of DRP-104, a broad glutamine antagonist, in adult patients with
OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting
Regulatory News:
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) announces the procedures for participating to the Combined General Meeting, to be held on June 24, 2021 at 2:30 p.m. CET.
As indicated in the press release dated May 19, 2021, the Combined General Meeting of June 24, 2021, will be held by live webcast, without the physical presence of shareholders or other persons usually eligible to attend pursuant to the provisions of the the order published on 25 March 2020 extended and amended by order no. 2020-1497 of 2 December 2020, decree no. 2020-418 of 10 April 2020 extended and amended by decree no. 2020-1614 of 18 December 2020 and decree no. 2021-255 of 9 March 2021.